SkinBioTherapeutics plc (AIM: SBTX)

Market Cap	37.12M
Revenue (ttm)	161.65K
Net Income (ttm)	-2.88M
Shares Out	228.44M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,885,139
Open	17.00
Previous Close	14.25
Day's Range	15.00 - 17.11
52-Week Range	7.00 - 20.68
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and op...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 11
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SBTX

Financial Performance

In 2023, SkinBioTherapeutics's revenue was 132,057, an increase of 76.64% compared to the previous year's 74,761. Losses were -2.84 million, 1.52% more than in 2022.